- Home
- GILD vs SNY Comparison
GILD vs SNY Comparison
Compare GILD & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- SNY
- Stock Information
- Founded
- GILD 1987
- SNY 1994
- Country
- GILD United States
- SNY France
- Employees
- GILD N/A
- SNY N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- GILD Health Care
- SNY Health Care
- Exchange
- GILD Nasdaq
- SNY Nasdaq
- Market Cap
- GILD 140.8B
- SNY 116.5B
- IPO Year
- GILD 1992
- SNY N/A
- Fundamental
- Price
- GILD $119.02
- SNY $49.04
- Analyst Decision
- GILD Buy
- SNY Buy
- Analyst Count
- GILD 24
- SNY 2
- Target Price
- GILD $114.26
- SNY $65.00
- AVG Volume (30 Days)
- GILD 6.4M
- SNY 2.6M
- Earning Date
- GILD 08-07-2025
- SNY 07-31-2025
- Dividend Yield
- GILD 2.65%
- SNY 3.26%
- EPS Growth
- GILD 496.80
- SNY 118.56
- EPS
- GILD 5.01
- SNY 8.65
- Revenue
- GILD $28,863,000,000.00
- SNY $53,714,621,258.00
- Revenue This Year
- GILD $1.91
- SNY $2.85
- Revenue Next Year
- GILD $3.75
- SNY $6.65
- P/E Ratio
- GILD $23.75
- SNY $5.67
- Revenue Growth
- GILD 3.81
- SNY 15.65
- 52 Week Low
- GILD $72.89
- SNY $44.73
- 52 Week High
- GILD $121.83
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- GILD 60.91
- SNY 53.96
- Support Level
- GILD $108.54
- SNY $46.14
- Resistance Level
- GILD $121.83
- SNY $47.54
- Average True Range (ATR)
- GILD 2.53
- SNY 0.82
- MACD
- GILD 0.67
- SNY 0.14
- Stochastic Oscillator
- GILD 78.86
- SNY 82.41
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.